About Us

ProFactor Pharma Limited (PFP) is a UK based company formed in 2009 by Professor John McVey and Dr Ian Garner, who had been working with recombinant human Factor VIII (rhFVIII) for over 25 years, together with co-founders Richard Cruse, Bruce Vernon and Hugh Ilyine, a team with many years of biotech experience.

Over the years, the PFP team has worked on the development of two rhFVIII’s, based on concepts developed by Prof. John McVey. Our lead asset is a standard half-life rhFVIII, produced by a patent protected CHO cell line that is high expressing for FVIII and a proprietary production process, leading to a high yield of rhFVIII. This enables us to manufacture a low-cost rhFVIII. With this lead asset, PFP aims to serve the large, untreated haemophila A patient population, living mostly in emerging markets, with no or limited access to a recombinant FVIII due to affordability.

This lead asset is undergoing some final tests to get it ready for further development in the clinic.

Our second asset is based on the same rhFVIII as our lead asset but includes some innovative modifications to enhance the half-life of FVIII. This novel approach to enhance FVIII half-life is currently being tested in a preclinical Proof-of-Concept study. It is expected that the same proprietary manufacturing process can be applied to this enhanced half-life rhFVIII, allowing to manufacture an enhanced half-life rhFVIII at a low cost as well.